
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : PBA-0111 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 21, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PBA-0405
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Presage Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
Details : PBA-0405 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 23, 2024
Lead Product(s) : PBA-0405
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Presage Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PBA-0405
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Presage Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Presage Announces FDA Study May Proceed to Evaluate Pre-GMP Candidate in Phase 0 Trial
Details : PBA-0405 is a novel ROR1 Inhibitor antibody with significantly improved therapeutic properties, which is currently being evaluated for the treatment of cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : PBA-0405
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Presage Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
